We report a 38-year-old man who presented in 1998 with advanced multiple myeloma and newly diagnosed diabetes mellitus (DM). Subsequent BMT has been successful after conditioning with melphalan and total body irradiation, but significant ischaemic retinopathy has developed. Chemotherapeutic agents, total body irradiation, and DM are likely to have been co-factors in precipitating the rapid onset of retinopathy. Routine ophthalmic surveillance is recommended for all patients after BMT, particularly for those with additional risk factors for the development of retinopathy such as DM. Bone Marrow Transplantation (2000) 26, 695-696. Keywords: bone marrow transplantation; total body irradiation; diabetes mellitus; cotton wool spot; radiation retinopathy
A 38-year-old man presented in June 1998 with advanced multiple myeloma (stage 3b) complicated by hypercalcemia and renal impairment. Initial treatment with infusional vincristine, adriamycin and dexamethasone (VAD) proved ineffective, but he achieved a partial response with intermediate dose melphalan (80 mg/m 2 i.v.). Type 2 diabetes was also diagnosed at the time of presentation, with a random blood sugar level of 29 mmol/l in the absence of ketonuria. Retinopathy was looked for and excluded at this time. Insulin was given, and he has since been maintained on twice daily insulin injections with good control of blood sugar levels.
In July of 1998 he developed a left sixth nerve palsy, with MRI evidence of a large sphenoid sinus plasmacytoma obliterating the pituitary fossa. Clinical hypopituitarism was present and he received 10 Gy of radiotherapy to the pituitary fossa as a matter of urgency. In view of his age and the fact that he had an HLAcompatible sibling donor, he was referred for allogeneic BMT. This took place in September 1998, following conditioning with melphalan 110 mg/m 2 and TBI (12 Gy in six fractions). Cyclosporine (5 mg/kg loading dose i.v., 2.5 mg/kg daily maintenance, adjusted according to serum levels) and methotrexate were given for GVHD prophylaxis. Post-transplant assessment at 3 months showed he had achieved a complete remission, with disappearance of urinary light chains and a normal bone marrow. Present treatment consists of penicillin V, insulin, nifedipine, clonidine, clodronate, thyroxine and hydrocortisone.
In April 1999, 7 months post transplant, he was referred for ophthalmic assessment after a routine optometric visit led to the discovery of extensive retinopathy, including retinal haemorrhages and cotton wool spots (see Figure 1) . Visual acuity has been well maintained at 6/6 right and left, and the patient has no visual difficulties. No ophthalmic treatment has been given, and the retinal appearances have changed little since first seen and photographed.
Discussion
This man's diabetes was diagnosed less than 2 years ago, and no ophthalmoscopic evidence of retinopathy was then present. It is therefore unlikely that the present retinal appearances could be due solely to diabetes bearing in mind the subsequent development of florid bilateral cotton wool spots. These are localised retinal nerve fibre layer infarcts and are usually seen only after many years of established and clinically evident background retinopathy.
In this case it is more likely that pituitary radioablation, TBI and chemotherapy together account for the florid retinopathy. Another potential contributory factor, namely chronic graft-versus-host disease, has fortunately not developed.
Radiation retinopathy (RR) is well described. 1,2 Neural retina, like the rest of the central nervous system, is highly radio-resistant, but the retinal micro-vasculature is not. Probably only 5% or so of normal eyes will develop RR following exposure to 45 Gy in 1.8 to 2.0 Gy fractions, usually after about 18 months. 2 Early changes include telangiectases, retinal haemorrhages and microaneurysms, progressing to cotton wool spots, macular oedema and ulti- mately retinal neovascularisation as ischaemia worsens. Optic atrophy, rubeosis iridis and neovascular glaucoma are further late complications. In this case, the total radiation dose did not exceed 22 Gy, yet marked retinopathy became apparent after only 6 months.
It is probable that high-dose chemotherapeutic agents used along with TBI prior to BMT in some way sensitise the retina to the effects of radiation, reducing the amount required to precipitate retinopathy and hastening the onset. Experimental evidence for this exists in the case of cytarabine hydrochloride:
3 by inhibiting DNA polymerase it may retard or prevent the DNA repair mechanisms that can combat the DNA lysis occurring after radiation exposure. Melphalan, the principal chemotherapeutic agent in this case, is a bifunctional alkylating agent, binding with and crosslinking DNA such that it prevents cell replication. Radiation-mediated DNA lysis leading to cell death would therefore be expected to have a more damaging effect.
Pre-existing diabetic retinopathy has been reported to potentiate the development of RR. 4 This would be in keeping with the known effects of diabetes on the retinal vascular endothelium and pericytes, the two retinal cell populations most at risk from radiation damage. In this patient no diabetic retinopathy was apparent at the time of radiation exposure, though it is possible that some subclinical vascular damage had already occurred, notwithstanding the short duration of diabetes.
Patients undergoing TBI and BMT are at risk of sight threatening retinopathy, and pre-existing DM is likely to increase this risk. We suggest that ophthalmic surveillance is arranged for these patients in the post-transplant period so that retinopathy can be detected early and managed appropriately.
